2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12E.05 Exploring Clinical Characteristics and Treatment Outcomes of Squamous Cell Lung Cancers Harboring EGFR and ALK Mutations: A Case Series

EP.12E.05 Exploring Clinical Characteristics and Treatment Outcomes of Squamous Cell Lung Cancers Harboring EGFR and ALK Mutations: A Case Series

Back to course

Pdf Summary

This case series examines the clinical characteristics and treatment outcomes of squamous cell lung cancer (SCC) patients with rare EGFR and ALK mutations. Conducted at the Sylvester Comprehensive Cancer Center between 2019 and 2024, the study retrospectively analyzed data from three female, never-smoking patients aged 64-71. The patients presented with locally advanced or metastatic Stage III/IV SCC and demonstrated either EGFR or ALK alterations.<br /><br />Two of the patients had mixed adenocarcinoma-squamous histology (one ALK, one EGFR), while the third had pure squamous histology. One patient with Stage IIIB disease underwent induction chemotherapy followed by surgery and adjuvant osimertinib, achieving a progression-free survival (PFS) of 23 months. Among the three patients, one experienced brain metastasis with squamous histology, retaining the EGFR mutation.<br /><br />The study found that treatment tolerance was similar to adenocarcinoma patients, with common adverse events like skin and gastrointestinal toxicities from osimertinib. The response to platinum-based chemotherapy varied, showing no consistent resistance patterns. <br /><br />Treatment responses were observed for therapies targeting EGFR/ALK mutations, particularly in non-smokers with adenosquamous or pure SCC histology. Despite observed heterogeneity in responses, osimertinib emerged as a promising treatment option. The study concludes that EGFR/ALK mutations, though uncommon in SCC, are critical therapeutic targets. Osimertinib appears beneficial, but additional research is necessary to understand the diverse response and resistance patterns to targeted therapies in SCC. <br /><br />In summary, the study highlights the potential of osimertinib in treating SCC patients with EGFR/ALK mutations, particularly non-smokers, but also underscores the need for further investigation into treatment variability and resistance.

Asset Subtitle

Priya Chattopadhyay

Meta Tag

Speaker Priya Chattopadhyay

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

squamous cell lung cancer

EGFR mutations

ALK mutations

osimertinib

adenosquamous histology

treatment outcomes

Sylvester Comprehensive Cancer Center

progression-free survival

platinum-based chemotherapy

treatment resistance